AbbVie | ABBV - Current Assets


AbbVie reported $33.67B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Abbott USD 25.51B 488M Mar/2026
ALKERMES USD 1.52B 164.26M Jun/2026
Amgen USD 31.48B 2.42B Mar/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Eisai JPY 883.01B 121.38B Jun/2026
Eli Lilly USD 54.84B 794M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
J&J USD 59.77B 601M Jun/2026
Medtronic USD 24.07B 75M Dec/2025
Merck USD 35.02B 8.5B Mar/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Novartis USD 27.35B 744M Jun/2026
Pacira USD 514.96M 33.01M Mar/2026
Perrigo USD 2.71B 85M Mar/2026
Pfizer USD 41.36B 1.46B Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026
UCB EUR 6.05B 733M Dec/2025
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
United Therapeutics USD 2.87B 830.5M Mar/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026
Zoetis USD 6.47B 294M Mar/2026